Davis's Drug Guide
deuruxolitinib
General
Genetic Implications:
Pronunciation:
due-rux-oh-li-ti-nib
Trade Name(s)
- Leqselvi
Ther. Class.
none assigned
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Deuruxolitinib." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580042/all/deuruxolitinib.
Vallerand AHA, Sanoski CAC, . Deuruxolitinib. Davis's Drug Guide. F.A. Davis Company; 2025. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580042/all/deuruxolitinib. Accessed April 16, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Deuruxolitinib. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580042/all/deuruxolitinib
Vallerand AHA, Sanoski CAC, . Deuruxolitinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 April 16]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580042/all/deuruxolitinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - deuruxolitinib
ID - 3580042
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580042/all/deuruxolitinib
PB - F.A. Davis Company
ET - 19
DB - Medicine Central
DP - Unbound Medicine
ER -
